UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment

Horton, Rebecca H; Saade, Dimah; Markati, Theodora; Harriss, Elinor; Bonnemann, Carsten G; Muntoni, Francesco; Servais, Laurent; (2022) A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment. Journal of Neurology, Neurosurgery & Psychiatry 10.1136/jnnp-2022-329431. (In press). Green open access

[thumbnail of Muntoni_AAV Gene Therapy Final for Open Access (without tables).pdf]
Preview
Text
Muntoni_AAV Gene Therapy Final for Open Access (without tables).pdf - Other

Download (387kB) | Preview
[thumbnail of Muntoni_Tables for SRAAV 37.pdf]
Preview
Text
Muntoni_Tables for SRAAV 37.pdf - Other

Download (7MB) | Preview

Abstract

Adeno-associated virus (AAV) gene therapies are generating much excitement in the rare disease field, particularly for previously untreatable neurological conditions. Efficacy has been claimed for several gene therapy products and the number of trials is rapidly increasing. However, reports of severe treatment-related adverse reactions are emerging, including death. There is still insufficient knowledge about their aetiology, prevention and treatment. We therefore undertook to systematically review publicly available data on AAV gene therapies in order to collate existing information on both safety and efficacy. Here, we review emerging efficacy reports of these novel therapies, many of which show promise. We also collate an increasing number of adverse reactions. Overwhelmingly, these results make a case for unified reporting of adverse events. This is likely to be critical for improving the safety of these promising treatments.

Type: Article
Title: A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1136/jnnp-2022-329431
Publisher version: http://dx.doi.org/10.1136/jnnp-2022-329431
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Psychiatry, Surgery, Neurosciences & Neurology, SPINAL MUSCULAR-ATROPHY, ACID DECARBOXYLASE DEFICIENCY, 1/2 CLINICAL-TRIAL, ONASEMNOGENE ABEPARVOVEC, OPEN-LABEL, IMMUNE-RESPONSES, REPLACEMENT THERAPY, SINGLE-ARM, FACTOR-IX, PHASE-I
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
URI: https://discovery.ucl.ac.uk/id/eprint/10157751
Downloads since deposit
589Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item